ESLA · Estrella Immunopharma, Inc. · Executive Compensation
$0.47
-0.01 (-1.47%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern. If the Company is unable to obtain adequate financing or generate significant revenue, it may be required to curtail or cease its operations.”View the 10-Q filed Aug 13, 2026
Market Cap
$20.92M
Shares
43.50M
Volume · Oct 2
14.49K
Avg daily vol (3M)
37.45K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jia Dengyao | member of the Board | Appointed | 2025-09-26 |
| Hong Zhang | member of the Company's Board of Directors | Appointed | 2024-08-20 |
| Hong Zhang | Chairperson | Appointed | 2024-08-20 |
| Peter Xu | Chief Financial Officer | Appointed | 2023-10-05 |
| Dr. Cheng Liu | Chief Executive Officer and President | Appointed | 2023-10-05 |